AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$AVR

L1 Capital Pty Ltd sold $4.1M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 495,189 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.30 ($8.23–$8.30, $4.11M total) across 2 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Aug 6, 2026, 10:48 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A large-holder open-market sale can affect sentiment, but without accompanying company news in the text, it is more likely to be a positioning signal than a fundamental reset.

02

Market read

Traders may monitor for follow-on selling or interpret the sale as a sentiment headwind, but the article does not provide new operational or financial information.

03

What to watch

Because the transaction is indirect and the filing lacks stated rationale, traders may over-weight it versus other upcoming catalysts (earnings, trial updates, financing).

Relevance 6/10Novelty 4/10Timing: filed 2026-08-06, covering sales on 2026-08-04 to 2026-08-05

Background

This is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp (AVR), reported by L1 Capital Pty Ltd as a 10% owner via indirect holdings.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 495,189 shares of Anteris Technologies Global Corp (AVR) for about $4.11M via open-market trades.

Expected impact

Near-term impact is likely limited, with focus on whether further selling continues or if the sale is routine under a 10b5-1 plan (here, none is stated).

Evidence & confidence

Form 4 provides transaction details and size, but the article does not include earnings, contracts, regulatory actions, or other company-specific catalysts that would reprice the stock.

Market effects

Sector

No sector-level implications are provided; this is a single-issuer Form 4 transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be non-informational (liquidity, diversification, tax, or planned disposition), especially since the filing does not state a 10b5-1 plan but still reflects a discrete, dated window.

Key entities

  • issuer
    Anteris Technologies Global Corp

    Company whose shares were sold; ticker AVR.

  • 10% owner
    L1 Capital Pty Ltd

    Reporter of the Form 4 transaction, selling shares via indirect holdings.

  • regulatory filing
    SEC Form 4

    Primary-source disclosure of insider transaction details.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVR insider trading history →

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min